|
Match
|
Document |
Document Title |
|
|
7026293 |
Treatment or prophylaxis of ischemic heart disease
The present invention provides a pharmaceutical composition and a method for reducing an infarct region resulting from the ischemic necrosis of cells, especially, a pharmaceutical composition and a...
|
|
|
7026292 |
Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
The present invention provides pharmaceutical compositions comprising a morphogenic protein stimulatory factor (MPSF) for improving the tissue inductive activity of morphogenic proteins,...
|
|
|
7022670 |
Neurotrophin NT-7 from carp
A purified neurotrophin, NT-7, including nucleic acid sequences encoding neurotrophin-7 isolated from Cyprinus carpio (carp) is described along with compositions derived therefrom.
|
|
|
7019115 |
Pro1017 polypeptides
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7008781 |
Method of enhancing the biological activity of ligands
Novel fusion polypeptide ligands that bind Eph family receptors or the Tie-2 receptor are identified, and methods for making the fusion polypeptide ligands in biologically active form are...
|
|
|
7008924 |
VGF fusion polypeptides
The present invention provides novel VGF polypeptides and selective binding agents. The invention also provides host cells and methods for producing VGF polypeptides. The invention further provides...
|
|
|
7005413 |
Combination therapy for conditions leading to bone loss
The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone...
|
|
|
6998239 |
Method for identifying a modulator of the binding of CCX CKR polypeptide to a chemokine
The invention provides polypeptides and polynucleotides encoding a novel chemokine receptor, CCX CKR. The invention further provides reagents and methods for identifying agents that modulate the...
|
|
|
6995244 |
Antagonists for human prolactin
A modified human prolactin molecule wherein the prolactin molecule comprises at least one mutation in a region selected from i) amino acids 41–57, ii) amino acids 94–110, and iii) amino acids...
|
|
|
6995136 |
Peptide fragments of murine epidermal growth factor as laminin receptor targets
A peptide factor, its analogs and methods of using such peptide factor derived from murine epidermal growth factor peptide is disclosed wherein the peptide factor is modified to protect it from...
|
|
|
6995245 |
Formation of novel erythropoietin conjugates using transglutaminase
The invention provides biologically active erythropoietin (EPO) conjugate compositions wherein a transglutaminase reaction is employed to covalently and site specifically conjugate the EPO molecule...
|
|
|
6992065 |
Sustained release formulations
A composition for sustained release comprises a carrier material containing a non-polymeric, non-water soluble liquid material having a viscosity of at least 5,000 cP at 37° C. that does not...
|
|
|
6991785 |
Method for administering a cytokine to the central nervous system and the lymphatic system
The present invention is directed to a method for delivering cytokines to the central nervous system and the lymphatic system by way of a tissue innervated by the trigeminal nerve and/or olfactory...
|
|
|
6992060 |
Prolonged efficacy of islet neogenesis therapy methods with a gastrin/CCK receptor ligand and an EGF receptor ligand composition in subjects with preexisting diabetes
Compositions and methods are provided for achieving in vivo islet cell regeneration in subjects with preexisting diabetes. The methods comprise short term treatment with a composition having a...
|
|
|
6989367 |
OBG3 globular head and uses thereof
The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight...
|
|
|
6987173 |
Process for the preparation of active somatotropin from inclusion bodies
A process for the preparation of biologically active somatotropin from inclusion bodies of a recombinant host cell containing an inactive form of said somatotropin protein comprises the steps of:
...
|
|
|
6979674 |
Polyol/oil suspensions for the sustained release of proteins
The present invention relates to the preparation of polyol/thickened oil suspensions containing a biologically active agent, for the sustained delivery of the biologically active agent. The...
|
|
|
6977160 |
Sensor protein and use thereof
The object of the present invention is to utilize, as a sensor protein, a molecular recognizing ability of a protein that scarcely undergoes any structural change by the binding of a target...
|
|
|
6972325 |
PRO273 polypeptides
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
6972178 |
Drug screening using a proline-rich nuclear receptor co-regulatory protein/nuclear receptor co-expression system
Assays are presented for screening for chemicals which affect the binding between proteins comprising an SH3 binding motif and nuclear receptor proteins. PNRC (Proline-rich Nuclear Receptor...
|
|
|
6967029 |
Method for increasing hematopoietic progenitor cells by stem cell factor
Novel stem cell factors, oligonucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders involving blood cells are also...
|
|
|
6967090 |
Nucleic acid and protein sequences of bovine epidermal growth factor
The invention provides a nucleotide sequence of bovine epidermal growth factor (bEGF) and the deduced amino acid sequence of the encoded protein. The invention further provides the nucleotide...
|
|
|
6964947 |
Stabilizing formulation for NGF
Formulations are provided comprising NGF and acetate-containing buffer from pH 5 to 6 that provide enhanced stability of NGF for use in promoting nerve cell growth, repair, survival,...
|
|
|
6962982 |
Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them
The present invention relates to the diagnosis of HIV infections. It especially teaches the production of a soluble retroviral surface glycoprotein- (or transmembrane glycoprotein)-chaperone...
|
|
|
6960444 |
Transcriptional mediators of blood vessel development and endothelial differentiation
This invention relates to methods of modulating the development of blood vessels and/or endothelial cell differentiation in a mammal comprising altering the activity of an Ets transcription factor,...
|
|
|
6956023 |
Materials and methods for providing nutrition to neonates
The subject invention provides methods for reducing or preventing villous atrophy and feeding intolerance in infants, particularly low birth weight and/or preterm infants, by enterally...
|
|
|
6953844 |
Isolation of neurotrophins from a mixture containing neurotrophin variants using hydrophobic interaction chromatography
Methods are provided for large scale purification of neurotrophins, including mature NGF, suitable for clinical use. The methods provide means to separate neurotrophins from various less desirable...
|
|
|
6951655 |
Pro-micelle pharmaceutical compositions
The present invention provides pro-micelle compositions comprising a pharmaceutically active agent encapsulated with a membrane of esterified C 12 -C 18 fatty acids. In the mammalian intestine,...
|
|
|
6946442 |
Method of hastening cervical ripening
The use of an agent for controlling vascular permeability within the cervix is disclosed for controlling cervical ripening. To hasten cervical ripening, the agent is one which increases vascular...
|
|
|
6946265 |
Nucleic acids and proteins with growth hormone activity
The invention relates to novel growth hormone activity (GHA) proteins and nucleic acids. The invention further relates to the use of the GHA proteins in the treatment of growth hormone related...
|
|
|
6946548 |
G-CSF analog compositions and methods
The present invention relates to granulocyte colony stimulating factor (“G-CSF”) analog polypeptide compositions, related nucleic acids, expression constructs, host cells, and processes for...
|
|
|
6939849 |
Recombinant PDGF A-chain homodimers and methods of use
DNA encoding two forms of PDGF A-chain polypeptide, the construction of expression vectors for expressing such DNA in yeast and mammalian cells, and the expression of such DNA in yeast and...
|
|
|
6939669 |
Expansion of hematopoietic cells using midkine or pleiotrophin
The present invention provides novel use of the MK family that is used alone as an agent for proliferating hematopoietic stem cells and hematopoietic precursor cells. The invention also provides an...
|
|
|
6936440 |
Selecting ligand agonists and antagonists
We have discovered that growth hormones from ternary complexes with their receptors in which site 1 on the hormone first binds to one molecule of receptor and then hormone site 2 then binds to...
|
|
|
6933277 |
Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides
This invention relates to a method for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with an ADNF polypeptide. In particular, the...
|
|
|
6933278 |
Treatment of hypertension using growth hormone in mammals subjected to fetal programming
Embodiments of this invention include methods for decreasing hypertension in mammals subjected to adverse cardiovascular fetal programming or a long-term adverse postnatal environment. Fetal...
|
|
|
6933134 |
DNA molecules encoding vascular endothelial cell growth factor II subunits
Vascular endothelial cell growth factor II is purified from the culture media used to maintain mammalian glioma cells. The protein is a heterodimer, stimulates mitogenesis of mammalian vascular...
|
|
|
6930089 |
Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke
Vascular endothelial growth factor, placenta growth factor or combinations of both including heteodimers are useful in the treatment or prevention of stroke or ischemic diseases in mammals.
|
|
|
6927282 |
Clarification of protein precipitate suspensions using anionic polymeric flocculants
Protein suspensions comprising soluble and insoluble components are purified via flocculation with anionic polymers, such as polyacrylamides, potato starch, or modified cellulose. The procedure...
|
|
|
6926910 |
Hydrophobe biomolecular structure
The present invention relates to a new hydrophobe biomolecular structure, which is compacted due to the passing of the structure over its point of collapse, a method for the preparation of the...
|
|
|
6924120 |
Chaperone protein containing an intramolecular chaperone-like sequence and its application to insulin production
The present invention relates to a chimeric protein containing an intramolecular chaperone (IMC) like sequence linked to a target protein, preferably an insulin precursor. The present invention...
|
|
|
6916786 |
Keratinocyte growth factor-2
This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such...
|
|
|
6916914 |
Purification of somatotropin from transformed microorganisms
This invention discloses a commercially advantageous process for extraction and purification of protein from microorganisms. The initial steps of the process are useful for purifying many insoluble...
|
|
|
6916913 |
Dorsalin-1 polypeptide and uses thereof
This invention provides an isolated vertebrate nucleic acid molecule which encodes dorsalin-1. This invention also provides a nucleic acid probe capable of specifically hybridizing with a sequence...
|
|
|
6916624 |
Antibodies that bind gamma-heregulin
A novel member of the heregulin superfamily has been identified which is designated “γ-HRG”. This molecule, secreted by human breast cancer MDA-MB-175 cells, leads to the formation of a...
|
|
|
6911206 |
Fusion proteins comprising carriers that can induce a dual immune response
The subject invention provides a fusion protein for producing a dual immune response in a vertebrate, which fusion protein comprises: (a) a first proteinaceous portion analogous to all or part of a...
|
|
|
6906029 |
Insulin-like growth factor binding protein (IGFBP-5)
A purified insulin-like growth factor binding protein (IGFBP) selected from the group consisting of insulin-like growth factor binding protein having an amino acid sequence that, preferably, is at...
|
|
|
6899882 |
Endothelial cell growth factor methods of isolation and expression
A novel growth factor specific for vascular endothelial cells has been identified in conditioned medium of bovine pituitary derived folliculo stellate cells. This factor, named folliculo stellate...
|
|
|
6897297 |
Hydrophobically-modified protein compositions and methods
Hydrophobically-modified proteins and methods of making them are described. A hydrophobic moiety is attached to a surface amino acid residue of the protein. The hydrophobic moiety can be a lipid or...
|
|
|
6897060 |
Composition comprising multipotent neural stem cells for generation of hematopoietic cells
Multipotent neural stem cell (MNSC) progeny are induced to generate cells of the hematopoietic system by placing the MNSC progeny in a hematopoietic-inducing environment. The hematopoietic-inducing...
|